Inotek Pharmaceuticals Secures $19 million Financing

"With several of our programs nearing clinical proof of concept,this round of financing provides us with the resources to generatefirst proof of efficacy data for at least three separate internaltherapeutic programs. It will also fund the expansion of ourdevelopment team to support our long-term growth," said AndrewSalzman, M.D., Inotek's President & CEO. "I am pleased by thecontinued support shown by our existing investors and look forward toworking with our newest partners, Meditor, Mitsubishi UFJ Capital, andHercules."

About Inotek Pharmaceuticals

Inotek Pharmaceuticals Corporation () is aprivate development-stage pharmaceutical company. Inotek has severalproducts in development targeting oncology, cardiovascular, andinflammatory diseases. All of Inotek's technologies were discoveredand developed by Inotek researchers.

The Company's lead program is focused on the development of potentoral and i.v. inhibitors of the nuclear enzyme poly (ADP-ribose)polymerase or PARP, which is in ongoing Phase 1b trials in oncologythrough Inotek's 2006 partnership with Genentech. The Company hasmultiple additional clinical and pre-clinical internal developmentprojects including two ongoing Phase 1 programs, one planned Phase 1program and a Next Generation PARP inhibitor program advancing throughpreclinical development.